BS
Bruce I Sachs (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). Across 1 priced purchase filing, the average 21-session return was +5.6% from execution and +2.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.9M of VRTX (5,000 sh across 2 lots, as filed), executed Aug 6 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+5.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+2.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.9M
shares × price, as filed
Last traded
Aug 6 2025
Filed Aug 7 2025
Median ADV $756.7M across their filed names
Open performance→Volume by month
Buys $1.9M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
VRTX
Vertex Pharmaceuticals Incorporated
VRTX · 1 buy · 0 sells
1 filing
Recent filings
VRTXPURCHASE
Vertex Pharmaceuticals Incorporated
View filing →
$1.9M5,000 sh across 2 lots
Exec Aug 6 2025
Filed Aug 7 2025 · 4:19 PM ET